ValuEngine downgraded shares of Bio-Rad Laboratories (NYSE:BIO.B) from a hold rating to a sell rating in a research report sent to investors on Friday morning.

Separately, TheStreet raised shares of Bio-Rad Laboratories from a c+ rating to a b- rating in a research note on Wednesday, November 29th.

Shares of Bio-Rad Laboratories (BIO.B) opened at $255.60 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 4.06 and a quick ratio of 2.77. The company has a market capitalization of $7,607.42, a PE ratio of 81.14 and a beta of 0.77. Bio-Rad Laboratories has a 52 week low of $176.50 and a 52 week high of $261.55.

COPYRIGHT VIOLATION NOTICE: “Bio-Rad Laboratories (BIO.B) Rating Lowered to Sell at ValuEngine” was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.